Legend Biotech exec details $100M lung cancer treatment deal

Legend’s subsidiary is licensing LB2102 and other potential CAR-T cell therapies targeting Delta-like ligand protein 3 to Novartis for $100 million upfront with the potential to receive up to $1.1 billion in milestone payments.

Related Keywords

Ireland , Switzerland , Swiss , Guowei Fang , Chong Kun Dang , Drug Administration , Legend Biotech Ireland , Novartis , Legend Biotech , Biotech Ireland Limited , Investigational New Drug , Orphan Drug Designation , South Korea Based , Chong Kun Dang Pharmaceutical ,